Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06904911
Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy (INTIMA-MT)
Sponsor: Genentech, Inc.
Interventions
intra-arterial tenecteplase administration
Updated 3 times since 2025 Last updated: Jan 7, 2026 Started: Dec 11, 2025 Primary completion: Sep 30, 2026 Completion: Sep 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Acute Ischemic Stroke From Large Vessel Occlusion and is currently actively recruiting participants. Genentech, Inc. leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
3 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2025 — Feb 2026 [monthly]
Not Yet Recruiting PHASE2
-
May 2025 — Nov 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Genentech, Inc.
- University of Pennsylvania
Data source: University of Pennsylvania
For direct contact, visit the study record on ClinicalTrials.gov .